United States Dental Implants & Abutments Market Outlook to 2033 - Dental Abutments and Dental Implants
Summary
GlobalData’s “United States Dental Implants & Abutments Market Outlook to 2033” is a comprehensive databook report, covering key market data on the United States Dental Implants & Abutments market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Dental Abutments and Dental Implants
The United States Dental Implants & Abutments Market report provides key information and data on -
Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
2023 company share and distribution share data for Dental Implants & Abutments Market.
Global corporate-level profiles of key companies operating within the United States Dental Implants & Abutments Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.
Scope
United States Dental Implants & Abutments is segmented as follows -
Dental Abutments
Dental Implants
Reasons to Buy
The United States Dental Implants & Abutments Market report helps you to develop -
Business strategies by identifying the key market segments poised for strong growth in the future.
Market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the market.
Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
Understand the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.
6.1.1 Integer Holdings Acquires Pulse for USD140 Million
6.2 Debt Offerings
6.2.1 Stryker Raises USD600 Million in Public Offering of 4.850% Notes due 2028
7 Recent Developments
7.1 Corporate Communications
7.1.1 Feb 12, 2024: Bittium Expands Its Range of Supported ECG Analysis Software by Collaborating With a Service Partner
7.1.2 Dec 11, 2023: FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism
7.1.3 Nov 21, 2023: Ingeneron Announces Critical In-Depth Analysis of the Results From a Recently Published 480-Patient Phase III Knee Osteoarthritis Trial
7.1.4 Nov 02, 2023: Dentsply Sirona Announces Appointment of Mr. Brian Gladden as New Board Member
7.1.5 Oct 13, 2023: Elos Medtech Notice to Attend the Extraordinary General Meeting
7.1.6 Oct 04, 2023: Boston University Names Melissa L. Gilliam 11th President
7.1.7 Sep 05, 2023: Zimmer Biomet Announces Key Updates to Company's Executive Leadership Team
7.1.8 Aug 22, 2023: Zimmer Biomet Announces Leadership Transition
7.2 Financial Announcements
7.2.1 Jul 08, 2024: Henry Schein to Webcast Second Quarter 2024 Conference Call on Tuesday, August 6, 2024 at 10:00 a.m. ET
7.2.2 Jul 01, 2024: Stryker to Announce Financial Results for its Second Quarter of Fiscal Year 2024
7.2.3 May 02, 2024: Zimmer Biomet Announces First Quarter 2024 Financial Results
7.2.4 Jan 10, 2024: HemoSonics' Quantra Hemostasis System with QStat Cartridge Wins 2024 Business Intelligence Group (BIG) Innovation Award in Healthcare Category
7.2.5 Dec 12, 2023: Chemdiv Presented Data for FLT3 Clinical Candidate at the 65th ASH Annual Meeting and Exposition with its Partners and Sponsors
7.2.6 Nov 16, 2023: Alphamab : Preliminary Results of a Phase I Clinical Trial of JSKN003 in Australia for the Treatment of HER2- Expressing Advanced Solid Tumors
7.2.7 Oct 17, 2023: Amplifier Therapeutics, a Cambrian Bio Pipeline Company, Doses First Patients in Phase 1B Clinical Trial and Closes New Financing From Future Ventures
7.2.8 Oct 02, 2023: Stryker to Announce Financial Results for Its Third Quarter of Fiscal Year 2023
7.3 Government and Public Interest
7.3.1 May 21, 2024: Henry Schein to Present at Investor Conferences in June 2024
7.3.2 Jan 03, 2024: Henry Schein to Present at J.P. Morgan’s Healthcare Investor Conference
7.3.3 Nov 07, 2023: Henry Schein to Present at Upcoming Investor Conferences in November 2023
7.3.4 Oct 09, 2023: Stryker to Host Investor Day
7.3.5 Sep 07, 2023: Envista Announces Participation in Baird Global Healthcare Conference
7.3.6 Sep 05, 2023: Henry Schein to Present at Investor Conferences in September 2023
7.4 Legal And Regulatory
7.4.1 Aug 09, 2023: Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
7.5 Product News
7.5.1 Jun 24, 2024: Zygoma Implants as an Alternative Rehabilitation for Sever Atrophy Cases
7.6 Strategy And Business Planning
7.6.1 Sep 28, 2023: TAE Life Sciences Celebrates Collaboration Milestones and Unveils Alphabeam for In-Hospital BNCT at ASTRO 2023 Annual Meeting